---
title: "Rheumatology"
order: 3
category: "Internal Medicine"
---

# Rheumatology

## Overview

Rheumatology is the medical specialty focused on the diagnosis and treatment of musculoskeletal diseases and systemic autoimmune conditions. These disorders, collectively known as rheumatic diseases, affect joints, muscles, bones, and connective tissues, and often have systemic manifestations involving multiple organ systems. Rheumatic diseases range from common conditions like osteoarthritis and gout to rare but serious autoimmune disorders like systemic lupus erythematosus and vasculitis.

### Scope of Rheumatology
- **Inflammatory arthritis**: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
- **Connective tissue diseases**: Systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome
- **Vasculitis**: Giant cell arteritis, granulomatosis with polyangiitis, polyarteritis nodosa
- **Crystal arthropathies**: Gout, pseudogout (CPPD)
- **Degenerative diseases**: Osteoarthritis
- **Metabolic bone diseases**: Osteoporosis, osteomalacia, Paget's disease
- **Soft tissue rheumatism**: Fibromyalgia, bursitis, tendinitis

### Epidemiology
- Rheumatoid arthritis: 0.5-1% of adults worldwide
- Systemic lupus erythematosus: 20-150 per 100,000 (higher in women and certain ethnicities)
- Gout: 3-6% of adults, increasing prevalence
- Ankylosing spondylitis: 0.1-1.4% of population
- Osteoarthritis: Most common joint disorder, affects >50% of adults over 65

### Common Presentations

**Joint symptoms**:
- **Arthralgia**: Joint pain without inflammation
- **Arthritis**: Joint inflammation with pain, swelling, warmth, and stiffness
- **Morning stiffness**: Duration helps distinguish inflammatory (>60 minutes) from mechanical (<30 minutes)

**Systemic symptoms**:
- Fatigue
- Fever
- Weight loss
- Rash
- Raynaud's phenomenon
- Sicca symptoms (dry eyes, dry mouth)

## Immunology in Rheumatic Diseases

### Autoimmunity Concepts

**Immune system dysregulation**:
- Loss of self-tolerance
- B cell and T cell activation against self-antigens
- Antibody production (autoantibodies)
- Immune complex formation and deposition
- Chronic inflammation

**Genetic susceptibility**:
- HLA associations: HLA-DR4 (RA), HLA-B27 (SpA), HLA-DR2/DR3 (SLE)
- Non-HLA genes: PTPN22, STAT4, IRF5

**Environmental triggers**:
- Infections (molecular mimicry)
- Smoking (RA)
- UV exposure (SLE)
- Silica exposure (systemic sclerosis)

### Autoantibodies in Rheumatic Diseases

**Rheumatoid arthritis**:
- Rheumatoid factor (RF): 70-80% sensitivity, 85% specificity
- Anti-CCP antibodies: 70-80% sensitivity, 95-98% specificity
- RF and anti-CCP both positive: High specificity for RA

**Systemic lupus erythematosus**:
- ANA: 95-98% sensitivity (screening test)
- Anti-dsDNA: 60-70% sensitivity, 95-98% specificity, correlates with disease activity
- Anti-Smith: 25-30% sensitivity, 99% specificity
- Anti-Ro/SSA and anti-La/SSB: Associated with Sjögren's syndrome, neonatal lupus

**Scleroderma**:
- Anti-Scl-70 (anti-topoisomerase I): Diffuse cutaneous SSc, ILD
- Anti-centromere: Limited cutaneous SSc (CREST syndrome)
- Anti-RNA polymerase III: Diffuse SSc, renal crisis

**Myositis**:
- Anti-Jo-1: Polymyositis, dermatomyositis with ILD

**ANCA-associated vasculitis**:
- c-ANCA (anti-PR3): Granulomatosis with polyangiitis
- p-ANCA (anti-MPO): Microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis

## Diagnostic Approaches

### Clinical Assessment

**History**:
- Joint involvement: Location, number, pattern (symmetric vs. asymmetric)
- Timing: Acute vs. chronic, inflammatory vs. mechanical pain
- Morning stiffness duration
- Extra-articular manifestations
- Family history of rheumatic diseases
- Medication history (drug-induced lupus)

**Physical examination**:
- **Joint examination**:
  - Inspection: Swelling, deformities, erythema
  - Palpation: Warmth, tenderness, effusion
  - Range of motion: Active and passive
  - Specific tests: Squeeze test (MCP/MTP), Schober test (AS)

- **Extra-articular**:
  - Skin: Rashes (malar, discoid, psoriatic), nodules, tophi
  - Eyes: Uveitis, scleritis, sicca
  - Lungs: Crackles (ILD)
  - Heart: Pericardial rub
  - Neurologic: Weakness, sensory changes

**Pattern recognition**:
- **Monoarthritis**: Septic arthritis, gout, pseudogout, trauma
- **Oligoarthritis** (<5 joints): Spondyloarthropathies, reactive arthritis
- **Polyarthritis** (≥5 joints): RA, SLE, viral arthritis
- **Axial involvement**: Ankylosing spondylitis, psoriatic arthritis

### Laboratory Testing

**Inflammatory markers**:
- ESR (erythrocyte sedimentation rate): Nonspecific, elevated in inflammation
- CRP (C-reactive protein): More specific for inflammation, rises faster than ESR
- Normal in some conditions (SLE, Sjögren's)

**Autoantibodies**:
- ANA: Screening for SLE and other CTDs
- RF and anti-CCP: RA
- Specific antibodies based on clinical suspicion

**Acute phase reactants**:
- Complement (C3, C4): Low in active SLE
- Ferritin: Very high in Still's disease, macrophage activation syndrome

**Synovial fluid analysis**:
- **Cell count and differential**:
  - Non-inflammatory: <2,000 WBC/μL (OA)
  - Inflammatory: 2,000-50,000 WBC/μL (RA, gout)
  - Septic: >50,000 WBC/μL (usually >80% PMNs)

- **Crystals**:
  - Monosodium urate: Negative birefringence (gout)
  - Calcium pyrophosphate: Positive birefringence (pseudogout)

- **Gram stain and culture**: Rule out septic arthritis

### Imaging

**Radiography (X-rays)**:
- Erosions, joint space narrowing
- RA: Marginal erosions, uniform joint space loss
- OA: Osteophytes, non-uniform joint space loss, subchondral sclerosis
- AS: Syndesmophytes, bamboo spine
- Gout: Punched-out erosions with overhanging edges

**Ultrasound**:
- Synovitis, erosions, tenosynovitis
- Crystal deposition (double contour sign in gout)
- Power Doppler for active inflammation

**MRI**:
- Early erosions and bone marrow edema
- Sacroiliitis in spondyloarthropathies
- Soft tissue involvement

**CT**:
- Detailed bone architecture
- ILD in CTD (high-resolution CT)

## Treatment Principles

### Pharmacologic Therapy

**Nonsteroidal anti-inflammatory drugs (NSAIDs)**:
- Mechanism: COX inhibition, reduce inflammation and pain
- Examples: Ibuprofen, naproxen, celecoxib (COX-2 selective)
- Side effects: GI (ulcers, bleeding), renal, cardiovascular (COX-2)
- Use lowest effective dose for shortest duration

**Glucocorticoids**:
- Rapid anti-inflammatory effect
- Systemic: Prednisone, methylprednisolone
- Intra-articular: Triamcinolone, methylprednisolone
- Side effects: Hyperglycemia, hypertension, osteoporosis, infection, weight gain
- Taper to lowest effective dose or discontinue

**Disease-modifying antirheumatic drugs (DMARDs)**:

**Conventional synthetic DMARDs (csDMARDs)**:
- **Methotrexate**: First-line for RA, weekly dosing, folic acid supplementation
- **Hydroxychloroquine**: SLE, RA, low toxicity
- **Sulfasalazine**: RA, spondyloarthropathies
- **Leflunomide**: RA, alternative to methotrexate
- Monitoring: CBC, LFTs, creatinine regularly

**Biologic DMARDs (bDMARDs)**:
- **TNF inhibitors**: Adalimumab, etanercept, infliximab, golimumab, certolizumab
  - Screen for TB and hepatitis B before starting
  - Risk of infections, malignancy (controversial)

- **IL-6 inhibitors**: Tocilizumab, sarilumab (RA, GCA)
- **B cell depletion**: Rituximab (RA, SLE, vasculitis)
- **T cell costimulation blocker**: Abatacept (RA)
- **IL-17 inhibitors**: Secukinumab, ixekizumab (psoriatic arthritis, AS)
- **IL-12/23 inhibitors**: Ustekinumab (psoriatic arthritis)

**Targeted synthetic DMARDs (tsDMARDs)**:
- **JAK inhibitors**: Tofacitinib, baricitinib, upadacitinib (RA, PsA)
  - Oral administration
  - Monitor for infections, thrombosis

**Treat-to-target approach**:
- Set specific disease activity goals (remission or low disease activity)
- Frequent monitoring (every 1-3 months)
- Escalate therapy if target not met
- De-escalate once sustained remission achieved

### Non-Pharmacologic Therapy

**Physical therapy**:
- Range of motion exercises
- Strengthening exercises
- Joint protection techniques

**Occupational therapy**:
- Assistive devices
- Splinting
- Activity modification

**Lifestyle modifications**:
- Weight loss (reduce joint stress)
- Smoking cessation (especially for RA)
- Regular exercise
- Dietary modifications (gout: limit purines, alcohol)

## Common Rheumatic Diseases

### Inflammatory Arthritis
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis and axial spondyloarthritis
- Reactive arthritis

### Connective Tissue Diseases
- Systemic lupus erythematosus
- Systemic sclerosis (scleroderma)
- Sjögren's syndrome
- Polymyositis and dermatomyositis
- Mixed connective tissue disease

### Crystal Arthropathies
- Gout
- Calcium pyrophosphate deposition disease (pseudogout)
- Calcium hydroxyapatite deposition

### Vasculitis
- Large vessel: Giant cell arteritis, Takayasu arteritis
- Medium vessel: Polyarteritis nodosa, Kawasaki disease
- Small vessel: ANCA-associated vasculitis, IgA vasculitis

### Degenerative and Metabolic
- Osteoarthritis
- Osteoporosis
- Paget's disease

## Key Points

- Rheumatic diseases encompass a diverse group of inflammatory, autoimmune, and degenerative conditions affecting joints and connective tissues
- Pattern recognition (number of joints, symmetry, extra-articular manifestations) is crucial for differential diagnosis
- Autoantibodies are important diagnostic tools but must be interpreted in clinical context; ANA has high sensitivity but low specificity
- Early aggressive treatment with DMARDs improves outcomes in inflammatory arthritis; methotrexate is first-line for RA
- Biologic and targeted synthetic DMARDs have revolutionized treatment of severe rheumatic diseases but require screening and monitoring for infections
- Treat-to-target strategy with regular monitoring and therapy escalation achieves better outcomes than symptom-based management

## References

1. Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR. Kelley and Firestein's Textbook of Rheumatology. 11th ed. Elsevier; 2020.

2. Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. 7th ed. Elsevier; 2018.

3. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.

4. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. Ann Rheum Dis. 2019;78(6):736-745.

5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update. Ann Rheum Dis. 2020;79(6):685-699.

6. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-1613.

7. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879-895.

8. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62(9):2569-2581.

9. Petri M, Orbai AM, Alarcón GS, et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.

10. van der Heijde D, Ramiro S, Landewé R, et al. 2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-991.
